Results 61 to 70 of about 6,428 (208)

Rimonabant-induced catatonia in schizophrenia: A case report

, 2009
Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease.
Sivakumar, Palanimuthu T., Gangadhar, Bangalore N., Arasappa, Rashmi, Behere, Rishikesh V., Divakaran, Anjith, Venkatasubramanian, Ganesan, Rao, Naren P., Reddy, Nalini N.   +7 more
core   +1 more source

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

Pharmaceuticals, 2010
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by ...
Fernando Cordido, Mª Luisa Isidro
doaj   +1 more source

Assessment of the Acute Toxicity and Anxiolytic‐Like Effect of α‐Humulene in Adult Zebrafish (Danio rerio)

Chemistry &Biodiversity, Volume 23, Issue 7, July 2026.
The monocyclic sesquiterpene α‐humulene elicited a significant anxiolytic‐like behavior in adult zebrafish and no observable acute toxicity. Pharmacological dissection suggested that this effect is independent of the benzodiazepine (BZD) binding site on the gamma‐aminobutyric acid (GABA) type A receptor (GABAAR), but it depends on the serotonin type 3 ...
Alex de Souza Borges, Italo Moura Barbosa, Jéssica Bezerra Maciel, Aluísio Marques da Fonseca, Jesyka Macedo Guedes, Jane Eire Silva Alencar de Menezes, Gyllyandeson de Araujo Delmondes, Marta Regina Kerntopf, Hélcio Silva dos Santos, Alexandre Magno Rodrigues Teixeira   +9 more
wiley   +1 more source

Anti-obesity activity of Erythrina subumbrans (Hassk.) Merr leaves extract in high fructose-induced obesity in Wistar rats [PDF]

Journal of HerbMed Pharmacology
Introduction: Obesity is known to lead to the development of metabolic disorders and Erythrina subumbrans (Hassk.) Merr has shown the potential in alleviating some diseases. This study aimed to assess the anti-obesity activity of the ethanol extract of E.
Elis Susilawati, Agus Sulaeman, Soni Muhsinin, Jutti Levita, Yasmiwar Susilawati, Sri Adi Sumiwi   +5 more
doaj   +1 more source

P.29 Involvement of Cannabinoid Receptors in Regulation of MMPs, Cell Proliferation and Apoptosis in Vascular Smooth Muscle Cells

Artery Research, 2020
Objectives: Cannabinoid receptors CB1R and CB2R are expressed in the vascular smooth muscle cells (VSMCs) and may contribute to vascular remodeling process (O’Sullivan, 2015).
Bettina Greiner, Manuela Sommerfeld, Ulrich Kintscher, Kai Kappert, Elena Kaschina   +4 more
doaj   +1 more source

A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials

Epilepsia, Volume 67, Issue 7, Page 3281-3299, July 2026.
Abstract Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.
Elisa R. Zanier, Ilaria Lisi, Elaine K. O'Loughlin, Federico Moro, Edilberto Amorim, David L. Brody, Daniel J. Correa, Dominique Duncan, Pavel Klein, Firas H. Kobeissy, Wolfgang Löscher, Edward J. Needham, Asla Pitkänen, Mary Jo Pugh, Jack Somers, Annamaria Vezzani, Amy K. Wagner, Laura S. Lubbers, International Conference on PTE Attendees, Denes Agoston, Edilberto Amorim, Sneha Anand, Hibah Awwad, Ginevra Bayon, Naima Belhachemi, Akash Bera, Costanza Bertani, Guido Bertolini, David L. Brody, Serena Brusatori, Francesca Buffelli, Aurora Chiapperini, Mara Chioccola, Severn Churn, Daniel J. Correa, Ramon Diaz‐Arrastia, Chris Dulla, Dominique Duncan, Chiara Ferlito, Aristea Galanopoulou, Angela Galic, Heidi Matos Galicia, Bin Gu, William Haskins, Victoria Johnson, Nigel Jones, Lowie Joseph, Pavel Klein, Firas Kobaissy, Ilaria Lisi, David Loane, Luther Loose, Laura S. Lubbers, Wolfgang Löscher, Edoardo Mazzone, Melissa Miller, Federico Moro, Edward J. Needham, Irma Wati Ngadimon, Terence O'Brien, Elaine K. O'Loughlin, Asla Pitkanen, Mary Jo Pugh, Teresa Giovanna Ravizza, Giuseppe Remuzzi, Massimo Rizzi, Rossella Di Sapia, Tawfeeq Shekh‐Ahmad, Doug Smith, Jack Somers, Kevin Staley, Francesca Tribuzio, Alexandra Ulyanova, Gloria Vegliante, Annamaria Vezzani, Joost Wagenaar, Amy K. Wagner, Kevin W. Wang, Justin Weppner, Peter J. West, Karen Wilcox, John Wolf, Elisa R. Zanier   +82 more
wiley   +1 more source

Rimonabant—Ein Cannabinoid-Rezeptor-Antagonist zur Gewichtsreduktion und Rauchentwöhnung

, 2005
Treatment of lifestyle risk factors such as and smoking is difficult. These risk factors play important roles in cardiovascular disease. Current therapeutic strategies only have minor impact on associated metabolic changes such as low HDL cholesterol and
Roberto Corti, Georg Noll, Riccardo Stacchi, Lukas Spieker   +3 more
core   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

What is the future for rimonabant in the treatment of obesity [PDF]

, 2008
Orlistat and sibutramine only cause modest reductions in body weight. Rimonabant, a cannabinoid receptor 1 antagonist, is a new approach to weight reduction, but is it safe, efficacious, and better than the existing ...
Doggrell, Sheila
core  

Efficacy of rimonabant in obese patients with binge eating disorder

, 2012
In obesity, a dysregulation of the endocannabinoid system has been shown. The endocannabinoid receptor blockage by rimonabant demonstrated interesting metabolic effects.
Gasteyger, Curt, Golay, Alain, Rissanen, A., Hanotin, C., Pataky, Zoltan, Ziegler, O.   +5 more
core   +1 more source